Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

H Zhang1, S Guttikonda, L Roberts

  • 1Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA.

Oncogene
|December 7, 2010
PubMed

Insights

Targeting Mcl-1, a key survival protein, shows promise for treating non-small-cell lung cancer (NSCLC). Silencing Mcl-1 effectively killed some NSCLC cells, suggesting a new therapeutic strategy for this deadly disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Non-small-cell lung cancer (NSCLC) has a low survival rate despite available therapies.
  • Cancer cells often exhibit defects in programmed cell death (apoptosis).
  • Bcl-2 family proteins (Bcl-2, Bcl-x(L), Mcl-1) regulate apoptosis and cell survival.

Purpose of the Study:

  • To investigate the role of Bcl-2 family members (Bcl-2, Bcl-x(L), Mcl-1) in NSCLC cell lines.
  • To determine if targeting Mcl-1 can be a therapeutic strategy for NSCLC.

Main Methods:

  • Analysis of Bcl-2 family member expression in fourteen NSCLC cell lines.
  • Silencing Mcl-1 or Bcl-x(L) expression using small interfering RNA (siRNA).
  • Investigating Mcl-1's interaction with BH3-only proteins (Noxa, Bim) and Bak in NSCLC cells.

Main Results:

  • NSCLC cell lines predominantly express high levels of Mcl-1 and Bcl-x(L), not Bcl-2.
  • Mcl-1 silencing potently killed a subset of NSCLC cell lines, while Bcl-x(L) silencing had limited effect.
  • The ratio of MCL1 to BCL-XL mRNA determined Mcl-1 dependency.
  • Mcl-1 was shown to sequester Noxa, Bim, and Bak, proteins involved in apoptosis.

Conclusions:

  • Mcl-1 plays a critical role in the survival of a subset of NSCLC cells.
  • Targeting Mcl-1, possibly by modulating its interaction with apoptotic proteins, may offer a novel therapeutic approach for NSCLC patients.